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Hepatic retransplantation is controversial because 
the results are inferior to primary transplants and 
organs are so scarce. To determine the factors that are 
associated with poor outcome within the first year 
following retransplantation, we performed a multivar-
iate analysis, using stepwise logistic regression, of 418 
hepatic retransplantations performed at a single insti-
tution from November 1987 to December 1993. The 
minimum follow-up was 1 year. Seven variables were 
found to be independently associated with subsequent 
graft failure (defined as either patient death or re-
transplantation): donor age (odds ratio 2.2 for each 
lO-year increase over age 45, 95% CI 1.3 to 3.7), female 
donor sex (odds ratio 1.7,95% CI 1.05 to 2.7), recipient 
age (odds ratio 1.6 for each 10-year increase over age 
45,95% CI 1.2 to 2.3), need for preoperative mechanical 
ventilation (odds ratio 1.8,95% CI 1.1 to 2.9), pretrans-
plant serum creatinine (odds ratio 1.24 for each in-
crease of 1 mg/dl, 95% CI 1.1 to 1.4), pretransplant total 
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serum bilirubin (odds ratio 1.4 for each 10-mg/dl in-
crease over 15 mg/dl, 95% CI 1.1 to 1.8), and the pri-
mary immunosuppressant, using tacrolimus as the ref-
erence category (odds ratio for cyclosporine·based 
immunosuppression 3.9, 95% CI 2.3 to 6.8). Although 
not part of the logistic regression model, the timing of 
retransplantation was also found to be important, 
with the overall probability of failure increasing from 
0.58 on day 0 to a peak of 0.8 on day 38 and decreasing 
slowly after that. The implications of these results reo 
garding the appropriateness of retransplantation are 
discussed. 
Hepatic retransplantation is a technically demanding pro-
cedure, and the overall results are inferior to those of pri· 
mary grafting (1-9). Although some reports have stressed 
that outcome has improved in recent years (5, 9), especially 
when considering so-called "elective" retransplantations (9, 
10), others feel that the failure rate is so high that the 
practice of retransplantation should be curtailed (11). 
An outright ban on hepatic retransplantation raises trou-
bling ethical questions, especially for those of us still grap· 
pIing with the apparent changing role of health profession· 
als: from the patient's advocate to agents of society (12, 13). 
It has also been pointed out that foreclosing the option of 
retransplantation would have a chilling effect on donor ac-
ceptance, as patients and their surgeons refuse to use any-
thing but the highest quality grafts (1). This could well have 
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the paradoxical effect of further limiting access to primary 
grafting. 
Practical and ethical considerations aside, our severe or-
gan shortage dictates that we apply the lessons learned in 
the past, so that we can make more efficient use of our scarce 
resources. To that end, we conducted a retrospective analysis 
of hepatic retransplantations carried out since the University 
of Wisconsin (UW)* (14) solution was adopted for organ pres-
ervation, in order to identify those risk factors that play a 
role in outcome. 
MATERIALS AND METHODS 
Patient population. From November 1, 1987 to December 31, 1993 
a total of 2019 adults underwent 2376 liver transplantations at 
Presbyterian University Hospital and the Veterans Administration 
Medical Center, Pittsburgh, Pennsylvania. Of these, 418 were re-
transplantations, and constitute the basis for this report. Cases were 
excluded if the liver was received as part of a multivisceral trans-
plant that included intestine. Minimum follow-up time was at least 
one year (censoring date: January 18, 1995). All grafts were flushed 
with UW solution (14) during cold preservation. 
Variables studied and endpoints. Recipient variables were age, 
sex, primary diagnosis, indication for retransplantation, time to re-
transplantation, UNOS status (United Network for Organ Sharing 
classification), need for preoperative mechanical ventilation, pri-
mary immunosuppressive agent (tacrolimus, cyclosporine, or tacroli-
mus rescue), whether the graft was an ABO mismatch, and the 
following preoperative laboratory measurements: total serum biliru-
bin, serum creatinine, and prothrombin time (as measured on the 
day of the retransplant or immediately before). 
Donor variables were age, sex, and total ischemia time. The pri-
mary endpoint was retransplanted graft failure; the cause of failure 
was the secondary endpoint. 
Definitions. Graft failure: Patient death or retransplantation. 
Medical urgency: UNOS I-stable patient, waiting at home; 
UNOS 2-waiting at home, but requiring medical support; UNOS 
3- unstable, in need of continuous hospitalization; or UNOS 4 -re-
quiring life-support systems. We should note that this classification 
was changed on April 1, 1995, but we use here the classification that 
was in effect during the study period. 
Total ischemia time: time elapsed from aortic cross-clamping in 
the donor to portal or arterial revascularization, or both simulta-
neously, in the recipient. 
Primary diagnosis: original liver disease (Table 1). 
Indications: the cause of graft failure for the preceding liver al-
lograft. 
Cause of retransplanted graft failure: 
1. Intraoperative- cardiac arrest of any cause. 
2. Neurological-including, but not limited to, hemorrhagic or 
ischemic cerebrovascular accident, central pontine myelinolysis, an-
oxic encephalopathy, and brain herniation. 
3. Cancer, de novo-including lymphoproliferative disease. 
4. Cancer, recurrent-recurrent hepatobiliary or extrahepatic can-
cer. 
5. Ischemic injury- damage of the allograft, either before revas-
cularization or afterward, that did not have a demonstrable immu-
nologic etiology. 
6. Primary nonfunction (PNF)-a graft with such poor initial 
function that an additional retransplantation or death occurred 
within two weeks, without identifiable technical or immunological 
cause of failure. 
* Abbreviations: HAT, hepatic artery thrombosis; MODS, multiple 
organ dysfunction syndrome; OLT, orthotopic liver transplant; PNF, 
primary non-function; ReTx, retransplantation; UNOS, United Net-
work for Organ Sharing; UW, University of Wisconsin. 















PBC,a PSC, cystic fibrosis, secondary biliary 
cirrhosis, biliary atresia, etc. 
Ethanol-induced cirrhosis 
Hepatitis B, hepatitis C, etc. 
a-I-antitrypsin deficiency, Wilson's disease, 
hemochromatosis, etc. 
All other etiologies of cirrhosis excluded 
Fulminant hepatic failure 
Hepatocellular carcinomab and 
cholangiocarcinoma 
Secondary hepatic malignancies 
Budd-Chiari syndrome, benign tumors, etc. 
a PBC=primary biliary cirrhosis; PSC=primary sclerosing 
cholangitis. 
b Excluding incidental tumors. 
7. Cardiac-including, but not limited to, congestive heart failure, 
arrhythmias, and acute myocardial infarction. 
8. Multiple organ dysfunction syndrome (MODS) (15)-without 
concomitant documented sepsis and when the liver dysfunction can-
not be attributed to identifiable primary hepatic processes. 
9. Sepsis-MODS from a documented bacterial, viral, or fungal 
infection (also known as secondary MODS (15)). When a patient died 
in the early posttransplant period with a documented infection, the 
assignment to sepsis, PNF (item 6) or ischemic injury (item 5) was 
made based on whether there was poor function from the beginning. 
Thus, a death from sepsis in a graft that never functioned was coded 
as PNF or ischemic injury. On the other hand, in a patient whose 
transplantation was performed during an unrecognized infection 
(e.g., positive blood cultures that are not reported until after the 
surgery), failure was attributed to sepsis without regard for the 
degree of initial dysfunction. 
10. Hepatitis, de novo-including hepatitis B. hepatitis C, cyto-
megalovirus, and adenovirus. 
11. Hepatitis, recurrent (self-explanatory) 
12. Technical, HAT-hepatic artery thrombosis and severe he-
patic artery stenosis. 
13. Technical, other-including, but not limited to, portal vein 
thrombosis, caval stenosis, ruptured pseudoaneurysms, hemorrhage 
after liver biopsy, biliary strictures (whether single or multiple), bile 
leaks, and bile cast syndrome. 
14. Rejection, acute-including acute cellular and humoral rejec-
tions (1). 
15. Rejection, chronic- occlusive arteriopathy or vanishing bile 
duct syndrome (11. 
16. Unknown-lost to follow-up, unclassifiable. 
17. Other (self-explanatory). 
Because multiple processes were operating simultaneously in 
most cases offailure, the assignment was made to the one considered 
to be the starting point of the morbidity cascade, or, if this was not 
identifiable, the most severe of the problems. Thus, when the al-
lograft dysfunction was the primary identifiable process (e.g., 
chronic rejection), this was the designated cause of failure rather 
than sepsis or MODS that occurred secondarily. Similarly, when a 
patient died of sepsis in the face of ongoing acute rejection, the cause 
of failure was assigned to rejection. The rationale in this circum-
stance was that the increased immunosuppression required to treat 
the acute rejection was the primary mortality factor whether or not 
this resulted in restoration of adequate liver function. Conversely, 
sepsis was considered the primary event in a patient whose infection 
led to discontinuance of immunosuppression followed by rejection. 
Statistical analysis. Continuous variables are presented as the 
mean :t standard deviation (SD), and categorical variables as frac-
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tions. A two-tailed t test was used to test for differences between 
means. Pearson's chi-square was used to test for differences between 
categorical variables. Unadjusted graft failure probabilities, as a 
function of time to retransplantation, were calculated by determin-
ing the graft failure rate for retransplants performed at each time 
point. 
Survival analysis was performed by means of the Kaplan-Meier 
method (16), with the log-rank test to compare strata. A Bonferroni 
adjustment was used for multiple comparisons. 
To calculate the probability that a graft will fail within one year of 
retransplantation, a stepwise logistic regression analysis (17) was 
carried out, starting with variables that achieved a significance level 
of :s: 0.3 in the screening univariate analysis. For categorical vari-
ables, preliminary univariate logistic regression models were fit to 
determine what subcategories could be properly grouped together. 
Models were fit using forward inclusion and backward elimination, 
with a likelihood ratio test. The presence of an interaction between 
variables was tested by introducing appropriate multiplicative 
terms. A significance level of 0.1 was used in the stepwise procedure. 
Mter a preliminary model was obtained, the functional relation 
between the continuous variables and the outcome was explored by 
fitting generalized additive models (18) in which the continuous 
variables were introduced as smooth terms, using a local regression 
procedure (19). A final logistic regression model was then fit, incor-
porating the appropriate functional form for the continuous vari-
ables. 
The generalized additive models and local regression procedures 
were done in S-Plus (StatSci Inc., Seattle WA). All other procedures 
were performed using SPSS (SPSS Inc., Chicago IL). 
RESULTS 
There were 2376 transplants performed on 2019 patients; 
1958 (82.4%) were primary grafts and 418 (17.6%) were re-
transplantations. Of the retransplantations, 341 (81.6%) 
were second grafts, 65 (15.6%) were third grafts, and 12 
(2.8%) were fourth grafts or higher. The leading indication 
for retransplantation was ischemic injury-PNF (40%), fol-
lowed by technical complications (26.5%, Table 2). There 
were 6 ABO mismatches, 3 of which failed (P = 0.54). 
Graft survival. Figure 1 shows the Kaplan-Meier graft 
survival curves stratified according to their prior transplant 
(OLT) status. At the end of each of the first 12 months, graft 
survival after retransplantation was 68-80% that of primary 
grafting (Table 3). The five-year graft survival was 59.5% 
(95% CI 57.1 to 61.9) for primary grafts and 35.5% (95% CI 
32.9 to 38.1) for retransplantations (P < 0.0005 for the over-
all survival distributions). Among the failed grafts, 62.4% 
were due to, or led to, patient death (58(J(, of the primaries 
and 75% of the retransplantations, P < 0.00005). A total of 
74% of the graft failures occurred within the first year (72% 
of the primaries and 81% of the retransplantations, P = 
0.004). Figure 2 shows the Kaplan-Meier graft survival 
TABLE 2. Indications for retransplantation 
----- ----
Indication Counta Percentage 
Ischemic injury-PNF 167 40.0 
Technical, HAT 75 17.9 
Technical, other 36 8.6 
Rejection, chronic 69 16.5 
Rejection, acute 14 3.3 
Hepatitis, recurrent 23 5.5 
Hepatitis, de novo 12 2.9 
Other 22 5.3 
a Total=418. 
Kaplan-Meier Graft Survival Curves According to 
1.0 Prior OL T Status 





a 0.6 ts -" 
--___ ..::.:.:: __ ~411 
~ 
LL 







- - - - - - Retransplantation 
0.0 
0 2 3 4 5 
Survival Time (yr) 
FIGURE 1. Kaplan Meier graft survival curves, stratified according 
to prior transplant status (whether they were primary grafts or 
retransplantations). The numbers along the curves denote the grafts 
at risk. 
TABLE 3. Monthly graft survival probabilities for first yeara 
Month PrimaryOLT Retransplant (n=1958) (n=41S) 
----
First 0.852 0.684 
Second 0.823 0.619 
Third 0.806 0.595 
Fourth 0.789 0.581 
Fifth 0.777 0.562 
Sixth 0.768 0.550 
Seventh 0.760 0.528 
Eighth 0.749 0.519 
Ninth 0.743 0.514 
Tenth 0.738 0.504 
Eleventh 0.732 0.500 
Twelfth 0.728 0.497 
a The numbers denote the Kaplan-Meier estimator of the proba-
bility of surviving to the end of the month. 
curves for retransplantations, stratified according to the 
transplant number. The only significant difference was that 
between second transplants and fourth or higher (P = 0.026). 
Causes of failure and timing of retransplantation. The 
leading cause of graft failure was sepsis-MODS, followed by 
technical complications, ischemic injury-PNF, and hepatitis 
(Table 4). Table 5 shows the distribution of the retransplants 
according to their timing (relative to the preceding trans-
plant). Slightly over half (51.7%) of the retransplants were 
performed within the first month of the preceding transplant, 
and almost 70% were carried out within the first six months. 
Figure 3 shows a plot of the probability of graft failure as a 
function of time to retransplantation (without adjusting for 
the effect of covariatesl. The probability of failure increases 
from 0.58 at day zero to 0.8 at day 38, decreasing slowly after 
that. 
Recipient factors. Table 6 shows the results of the screen-
ing univariate analysis of recipient characteristics, according 
to whether the graft survived more than one year (group I) or 
failed within this time (group II). There were no differences 
in terms of the original diagnosis or preoperative prothrom-
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FIGURE 2. Kaplan-Meier graft survival curves for retransplanta-
tions, stratified according to graft number. The numbers along the 
curves denote the grafts at risk. 
TABLE 4. Cause of graft failure after retransplantation 
Cause Counta Percentage 
Cancer, de novo 4 1.5 
Cancer, recurrent 8 3.1 
Cardiac 7 2.7 
Hepatitis, recurrent 12 4.6 
Hepatitis, de novo 6 2.3 
Intraoperative 6 2.3 
Ischemic injury-PNF 31 12.0 
Neurological 4 1.6 
Rejection, chronic 14 5.4 
Rejection, acute 2 0.8 
Sepsis-MODS 114 44.0 
Technical, HAT 20 7.7 
Technical, other 22 8.5 
Other 6 2.3 
Unknown 3 1.2 
a Total=259. 
TABLE 5. Time to retransplantation 
Month after prior OLT Number of OLTs" Percent Cumulative percent 
First 216 51.7 51.7 
Second 32 7.7 59.3 
Third 11 2.6 62.0 
Fourth 15 3.6 65.6 
Fifth 12 2.9 68.4 
Sixth 4 1 69.4 
Mter six months 128 30.6 100 
----- ------------------
a Total =418. 
bin time. All other recipient variables studied showed a sig-
nificant statistical association with outcome. 
Donor factors. Table 7 shows the donor characteristics 
according to outcome. Failed grafts (group II) were more 
likely to come from females and older donors. 
Logistic regression analysis. The results are presented in 
Table 8. Donor age, donor sex, recipient age, need for preop-
erative mechanical ventilation, preoperative serum creati-
0.80 
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FIGURE 3. Probability of graft failure as a function of time elapsed 
since the previous transplant. These are based on the gross failure 
rates (i.e., unaQjusted for the effect of covariatesl for grafts per-
formed at each time point. 
nine and bilirubin, and primary immunosuppression were all 
significantly associated with graft failure within one year. 
There was no evidence of interaction between the covariates. 
Mode and cause of failure. Males were more likely to die 
than females (77.4% of graft failures in male recipients were 
due to, or led to, patient death, as opposed to 68.1% in 
females), but this was only of borderline significance (P = 
0.1). There were no differences in the causes of graft failure 
when stratified according to recipient sex. 
Predicted probability of graft failure. Table 9 shows the 
predicted probabilities that a graft will fail within the first 
year of a retransplant, for selected hypothetical scenarios. 
These are calculated on the basis of the logistic regression 
model shown in Table 8. To perform the calculation, dichot-
omous variables are entered into the logistic equation as 
either zero (male donor, nonintubated, tacrolimus) or one 
(female donor, on mechanical ventilation, cyclosporine). For 
donor and recipient age, we use the number of years in excess 
of 45. For preoperative bilirubin, we use a bilirubin level in 
excess of 15. Finally, the serum creatinine is entered unmod-
ified. 
DISCUSSION 
A significant fraction of hepatic grafts continue to fail, 
especially in the early posttransplant period. In the present 
series, 27% of primary grafts and fully half of those retrans-
planted failed within one year (Figure 1 and Table 3), con-
sistent with what has been reported from other centers (8). 
Five-year graft survival following a primary transplant was 
59.5%, but only 35.5% after retransplantation. Most (62.4%) 
of the failures, primary as well as retransplants, were due to, 
or led to, patient death. However, there was still a substan-
tial number of patients whose lives were significantly pro-
longed by retransplantation (Fig. 2). 
Several factors were independently associated with graft 
failure within one year after retransplantation (Table 8), and 
were generally the same as previously reported in series with 
a preponderance of primary grafts: older and female donors 
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TABLE 6. Recipient characteristics according to retransplant outcomea 
Group I Group II Significance 
En~OMUF En~O1lF 








Sex(mJf) 107/101 132178 
Time to ReTx (days) 3692:690 2182:416 
Preoperative bilirubin (mg/dl) 15.62:12.6 20.02:14.9 
Preoperative creatinine (mg/dl) 2.12:1.5 2.7:!: 1.9 
Preoperative prothrombin time (s) 17.52:7.3 17.62:5.9 
UNOS 4 status ('!o) 80.8 89.0 
Preoperative mechanical ventilation (%) 47.2 62.5 
Primary immunosuppressant (%): 
Tacrolimus 60.1 58.4 
Cyclosporine 19.2 36.4 
Tacrolimus rescue 20.7 5.2 P<0.0005 
Indication for ReTx (%): 
Hepatitic 4.8 11.9 
PNF -ischemia 39.4 40.5 
Technical 30.3 22.9 
Acute rejection 2.4 4.3 
Chronic rejection 21.2 11.9 
Other 1.9 8.5 P=0.002 
Original diagnosis (%) 
Alcoholic 15.4 14.8 
Autoimmune 5.3 2.9 
Cholestatic 25.5 19.0 
Cryptogenic 12.5 9.0 
FHF 4.3 4.3 
HCC-cholangio. 3.4 7.6 
Hepatitic 25.0 30.5 
Other malignancy 0.5 1.9 
Metabolic 3.4 4.8 
Other 4.7 5.2 P=0.24 
a Group I=grafts surviving more than one year; group II = grafts that failed within 1 year. 
TABLE 7. Donor characteristics according to retransplant outcomea 
-- --
Group I Group II Significance (n=20S) (n=210) 
Age (yr) 30.12:14.3 35.02:14.7 P=O.OOl 
Female sex (%) 35.6 46.2 P=0.03 
Ischemia time (hr) 12.22:4.6 12.92:4.7 P=0.14 
a Group I=grafts surviving more than one year; group II = grafts 
that failed within 1 year. 
(20, 21), renal failure (22, 23), and extreme hyperbiliru-
binemia (22, 23). Interestingly, prolonged graft ischemia, a 
well-known risk factor (14, 21, 24), failed to achieve signifi-
cance in this analysis. There are several possible explana-
tions for this discrepancy, the most simple being that vari-
ables such as preoperative creatinine and need for 
mechanical ventilation, which were not included in some of 
our previous modeling attempts (21, 24), have more explan-
atory power than ischemia time. Another possibility is that 
this a reflection of the limitations inherent in trying to model 
patient death and retransplantation as a single outcome, as 
it is likely that some risk factors are more strongly associated 
with one or the other. In the present example, we find that 
our retransplantation cohort is a group at a higher risk for 
death (75% ofthe graft failures were caused by patient death, 
versus 58% after primary transplantation), and this may 
obscure the effects of ischemia time if this variable is more 
strongly associated with need for retransplantation than 
with patient death. We have found support for this notion by 
TABLE 8. Variables independently associated with graft failure 
f3" Odds ratio 95% CI 
Donor age 









0.08 2.2b 1.3 to 3.7b 
0.52 1.7 1.05 to 2.7 
0.05 1.6b 1.2 to 2.3h 






1.1 to 1.4c 
1.1 to 1.8d 
2.3 to 6.8 
a /3 = regression coefficient; the model also includes a con-
stant= ~OKM19K 
b For each 10-year increase over age 45. 
C For each increase of 1 mg/dl. 
d For each 10-mg increase over 15 mg/dl. 
f Includes tacrolimus-rescue cases. 
modeling both endpoints separately, as competing risks, in a 
large series of primary transplants (unpublished observa-
tions). The two other factors that emerged from this analysis 
were the choice of immunosuppressant and recipient age. 
The odds of failing were about four times greater in patients 
treated exclusively with cyclosporine (versus tacrolimus), 
which is consistent with previous reports from our center (21, 
25-27) and elsewhere (28-30). The last finding, recipient age, 
is in contrast to our previous observations (20, 21, 31), and 
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TABLE 9. Probability of graft failure after retransplantation under selected hypothetical scenarios 
-------------------------
Scenario 1 
Donor age (yr) 30 
Donor sex Male 
Recipient age 45 
Pretransplant mechanical ventilation No 
Pretransplant creatinine (mg/dl) 2 
Pretransplant bilirubin (mg/dl) 15 
Immunosuppressant Tacrolimus 




























a Calculated probability, using the logistic regression model of Table 8. 
will require further studies of larger samples for confirma-
tion. 
The timing played an important role in the outcome of 
retransplantation, the probability of eventual graft failure 
increasing from 0.58 to 0.8 between days 0 and 38, and 
decreasing slowly thereafter (Fig. 3). Presumably, this re-
flected worsening multiple organ dysfunction as a result of a 
poorly functioning liver allograft, the recovery of which was 
awaited in vain; the slowly diminishing risk after the fifth 
week is most likely simply a reflection of natural selection. 
Similarly, Powelson et al. (8), found that patients retrans-
planted within the first three days had a 57% graft survival, 
versus 24% for those retransplanted between days 4 to 30 (8). 
The need for early recognition of patients who require re-
transplantation was one of the earliest lessons in this field (2, 
3), and the motivation for our previous work in outcome 
prediction (23, 32). Other ways of improving the outcome of 
retransplantation are listed in Table 8: younger, male donors 
and optimum immunosuppression. 
Some might argue that the preceding paragraph begs an 
important question: given the severe organ shortage, should 
we offer retransplantation as an option? Saying that it is 
unfair to allow a patient to receive multiple transplants, 
while others wait for their first one, does not hold up to 
careful scrutiny, as even critics of the present system point 
out (11). Aside from producing an ethical quagmire of patient 
abandonment, a "one organ, one recipient" mandate would 
inhibit current efforts to expand the organ pool by acceptance 
of marginal donors. The safety net of retransplantation is 
implicit in these initiatives. 
In addition, grouping all retransplantations together is a 
dangerous oversimplification. All authors who have investi-
gated outcome variables have found differential risk catego-
ries. With the information already available, individualized 
prognoses can be formulated. For example, a 45-year-old 
patient with a bilirubin of 15 mg/dl and a creatinine of 2 
mg/dl, who is not intubated, has a calculated probability of 
graft failure (within one year) of only 0.17 if tacrolimus is 
used along with a liver from a male donor less than 45 years 
of age. On the other hand, if the same patient has a bilirubin 
of 50 mg/dl and a creatinine of 5 mg/dl, and requires mechan-
ical ventilation; receives a liver from a 65 year old female; 
and is given cyclosporine-based immunosuppression, the cal-
culated probability of failure is 0.99 (Table 9). The calculated 
risk under the first scenario would be acceptable to most 
people, even for a primary transplant, whereas the second 
would not. 
We should emphasize that unless the model is validated 
prospectively these probability estimates cannot be accepted 
at face value. However, they agree with the clinical impres-
sion of most experienced liver transplant surgeons, and illus-
trate the point that not all retransplant procedures are cre-
ated equal. We agree that the very liberal retransplantation 
policies of the past cannot be justified any longer, and one of 
the challenges is to decide which patients should be offered 
retransplantation, and which should not. Predictive models 
such as the one described in this report provide a reasonable 
starting point for this endeavor. 
Although on average retransplantations are undoubt-
edly more costly than the primary procedure (33, 34), 
D'Allesandro et al. found that retransplantations carried out 
during a separate admission had a cost and length of stay 
similar to that of an initial liver replacement (9). As with 
other medical procedures, cost benefit analyses of retrans-
plantation must take into account the differences in severity 
of illness, all factors associated with such efforts, and - most 
important- the degree of rehabilitation of patients who sur-
vive by virtue of these efforts and return to a meaningful role 
in society. 
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